Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-426-2 | CAS number: 140-66-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Specific investigations: other studies
Administrative data
Link to relevant study record(s)
- Endpoint:
- endocrine system modulation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: meets generally accepted scientific standards, well documented and acceptable for assessment
- Qualifier:
- according to guideline
- Guideline:
- other: Hershberger Assay (OECD 2001)
- Principles of method if other than guideline:
- Chemicals are administered orally for 10 days to castrated rats.
- GLP compliance:
- yes
- Type of method:
- in vivo
- Endpoint addressed:
- not applicable
- Species:
- rat
- Strain:
- other: Brl Han: WIST Jcl (GALAS)
- Sex:
- male
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 10 d
- Frequency of treatment:
- daily
- Post exposure period:
- 24-h after final dose
- Remarks:
- Doses / Concentrations:
50 mg/kg
Basis:
nominal conc. - Remarks:
- Doses / Concentrations:
200 mg/kg
Basis:
nominal conc. - Remarks:
- Doses / Concentrations:
400 mg/kg
Basis:
nominal conc. - Remarks:
- Doses / Concentrations:
600 mg/kg
Basis:
nominal conc. - No. of animals per sex per dose:
- 6
- Control animals:
- yes, concurrent vehicle
- Conclusions:
- In this Hershberger assay study male castrated rats were administered 50, 200 and 600 mg/kg bw octylphenol. Animals receiving 200 mg/kg bw showed decreased body weight gain and decreased spontaneous locomotion. Death occurred at the highest concentration. No significant dose related changes of the sex organ weights were noted. Co-administration with Testosterone propionate caused an increase in the relative weight of the Cowper’s gland at 200 mg/kg day.
- Executive summary:
- In a study to assess estrogenic and androgenic properties
4-tert-octylphenol was administered to 6 male Brl Han: WIST Jcl (GALAS)
rats by oral gavage at dose levels of 50, 200 and 600 mg/kg bw/day.
Parallel groups of animals were co-administered with Testosterone
propionate (TP).
All rats given 600 mg/kg bw 4-tert-octylphenol as well as those given 600 mg/kg bw plus TP died during the administration period. Treatment with 200 mg/kg bw 4-Tert-octylphenol resulted in significant body weight loss. For all groups, the accessory sex organ weight values are within the control ranges. The relative seminal vesicle weights increased significantly in the low-dose group only (50 mg/kg bw 4-tert-ocylphenol). The relative Cowper’s gland weight increased in rats co-administered with TP at 200 mg/kg bw but an apparent dose dependency was not observed. The seminal vesicle weight in this group was within the control ranges of other studies. From the data provided it cannot be concluded that octylphenol acts as an estrogen agonist or androgen antagonist.
- Endpoint:
- endocrine system modulation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: meets generally accepted scientific standards, well documented and acceptable for assessment
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Yeast assay (Saccharomyces cerevisiae) - the oestrogenic activity was expressed as a potency relative to 17ß-estradiol
- GLP compliance:
- not specified
- Type of method:
- in vitro
- Endpoint addressed:
- not applicable
- Species:
- other: yeast
- Strain:
- other: Sacccharomyces cerevisiae
- Sex:
- not specified
- Route of administration:
- other: assay
- Vehicle:
- ethanol
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 84 h
- Frequency of treatment:
- single
- Post exposure period:
- 7 d
- Remarks:
- Doses / Concentrations:
5-60 mM
Basis:
other: stock solutions of the chemicals were made up in ethanol and diluted to achieve final concentrations - No. of animals per sex per dose:
- Duplicates applied into wells of optically flat 96-well microtiter plates.
- Control animals:
- yes, concurrent vehicle
- Details on results:
- In a comparative study of alkyl phenols with the main natural estrogen 17ß-estradiol, 4-tert-octylphenol was found to be about 1 000 times less potent than 17ß-oestradiol.
- Conclusions:
- In a comparative study of alkyl phenols with the main natural estrogen 17ß-oestradiol, 4-tert-octylphenol was found to be about 1000 times less potent than 17ß-oestradiol.
- Executive summary:
In a study on endocrine system modulation, 4 -tert-Octylphenol (99 % a.i.) was tested applied at concentrations of 5 -60 mM to optically flat 96-well microtiter plates containing recombinant yeast as assay medium. After 84 hour incubation, absorbance of 540 nm was read and compared to that of 17ß-estradiol. Control animals received the concurrent vehicle. After the post exposure period of 7 days, 17ß-estradiol was found to be about 1000 times more potent than 4-tert-octylphenol. Tamoxifen, an estrogen antagonist known to act via the estrogen receptor, was shown to inhibit the activity of the alkyl phenols, demonstrating that the assay response was due to interaction with the estrogen receptor.
This study is classified acceptable, it meets generally accepted scientific standards, is well documented and acceptable for assessment.
- Endpoint:
- endocrine system modulation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Meets generally accepted scientific standards, well documented and acceptable for assessment
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- rat uterine cytosolic (RUC) ER-competitive binding assay
- GLP compliance:
- not specified
- Type of method:
- in vitro
- Endpoint addressed:
- not applicable
- Details on results:
- This study was conducted to characterize the estrogen receptor (ER)–binding affinity of 4-(1,1,3,3,-Tetramethylbutyl)-phenol using the rat uterine cytosolic (RUC) ER-competitive binding assay, with secondary analysis using Lineweaver-Burk plots and slope replots to confirm true competitive inhibition and to determine an experimental Ki. The inhibitory concentration (IC 50) of 4-(1,1,3,3,-Tetramethylbutyl)-phenol was reported as 12.0 µM compared to 0.00052 µM for 17 -b–Estradiol.
- Conclusions:
- The inhibitory concentration (IC 50) of 4-(1,1,3,3,-Tetramethylbutyl)-phenol was reported as 12.0 µM compared to 0.00052 µM for 17 -b–Estradiol.
- Executive summary:
This study was conducted to characterize the estrogen receptor (ER)–binding affinity of 4-(1,1,3,3,-Tetramethylbutyl)-phenol using the rat uterine cytosolic (RUC) ER-competitive binding assay, with secondary analysis using Lineweaver-Burk plots and slope replots to confirm true competitive inhibition and to determine an experimental Ki. The inhibitory concentration (IC 50) of 4-(1,1,3,3,-Tetramethylbutyl)-phenol was reported as 12.0 µM compared to 0.00052 µM for 17 -b–Estradiol.
This study is acceptable, it meets generally accepted scientific standards, is well documented and acceptable for assessment.
- Endpoint:
- specific investigations: other studies
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- March 1996
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Meets generally accepted scientific standards, well documented and acceptable for assessment.
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Assessment of effects on uterine growth on immature female rats. All animals received a single dose (10 mg/kg bw) Octylphenol via oral gavage on each day for three days. The animals were terminated 24 hours after the final dose. A preliminary range-finding study was conducted to evaluate the maximum tolerated dose.
- GLP compliance:
- no
- Type of method:
- in vivo
- Endpoint addressed:
- toxicity to reproduction / fertility
- Species:
- rat
- Strain:
- other: Alpk:APfSD (Wistar-derived)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source:BABU, Alderely Park, Cheshire, UK
- Age at study initiation: (3) x wks; (F1) x wks
- Weight at study initiation: (P) Females: 37-48 g; (F1) Males: x-x g; Females: x-x g
- Housing: 6 per cage
- Diet (e.g. ad libitum): PCD, ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 24 h
ENVIRONMENTAL CONDITIONS
- Temperature (°C): standard conditions
- Humidity (%): standard conditions
- Photoperiod (hrs dark / hrs light): standard conditions - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
All dosings were prepared on the day dosing commenced and were stored at room temperature throughout the dosing period.
DIET PREPARATION
- Rate of preparation of diet (frequency): daily
- Mixing appropriate amounts with (Type of food): PCD diet
- Storage temperature of food: room temperature
VEHICLE
- Justification for use and choice of vehicle (if other than water): no data
- Concentration in vehicle: not analyzed
- Amount of vehicle (if gavage): 10 ml/kg - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 3 days
- Frequency of treatment:
- daily
- Remarks:
- Doses / Concentrations:
100, 200, 300, 400 mg/kg/bw
Basis:
actual ingested - No. of animals per sex per dose:
- 6 animals per dose (all females)
- Control animals:
- yes, concurrent vehicle
- other: yes, positiv control: oestradiol benzoate (0.5 µg/animal, subcutaneously)
- Details on study design:
- The body weight of each animal was recorded upon delivery immediately prior to dosing on each day to termination.
Clinical observations were conducted prior to the start of the study as well as at the time of weighing and dosing. The rats were observed at least once daily (post-dosing) during the study.
Day of termination: 24 h after the third and final dose. An overdose of inhalation anaesthetic (fluorethane) was used. The uterus was removed from each animal, trimmed and blotted on filter paper to remove any fluid. The uterus was then weighed and discarded. - Conclusions:
- Octylphenol produced a slight but statistically significant increase in relative (not absolute) uterine weight at all dose levels. However, the biological importance of this slight response remains unclear. The results indicate that octylphenol does not possess the intrinsic potential to mimic oestrogen action, under the conditions of this study.
- Executive summary:
Octylphenol was administered to 6 immature female Alpk:APfSD (Wistar-derived) rats/dose by gavage at dose levels of 0, 100, 200, 300, and 400 mg/kg bw/day for three consecutive days. A slight but statistically significant increase in relative uterine weight at all dose levels was reported (1.18 - 1.31 -fold). The biological importance of this slight response remains unclear. It cannot be concluded that octylphenol possesses an intrinsic potential to mimic oestrogen action, under the conditions of this study.
The NOAEL on uterine weight is 400 mg/kg bw/day in immature females.
This uterotrophic assay in the rat is classified acceptable for assessment of the estrogenic activity of Octylphenol.
Referenceopen allclose all
Hershberger Assay - adminstration of 4-tert-octylphenol with and without testosterone propionate (TP) for 10 days
Doses (mg/kg per day) |
Body Weight (g) |
Ventral Prostate (mg/100 g bw) |
Seminal vesicle (mg/100 g bw) |
BC/LA (mg/100 g bw) |
Glans penis (mg/100 g bw) |
Cowper’s gland (mg/100 g bw) |
Vehicle control |
281.9±7.9 |
5.2±0.7 |
10.2±1.2 |
50.0±5.4 |
11.6±1.3 |
1.2±0.4 |
50 |
278.7±9.5 |
5.9±0.9 |
11.6±0.7* |
50.8±6.7 |
12.8±1.4 |
2.1±1.1 |
200 |
256.7±15.3** |
5.8±0.9 |
10.4±1.9 |
49.4±7.8 |
12.3±2.1 |
1.7±0.4 |
600(400)# |
- |
- |
- |
- |
- |
- |
Vehicle control +TP |
285.0±14.4 |
36.4±4.6 |
76.9±18.3 |
113.5±12.9 |
24.0±2.6 |
6.8±0.9 |
50+TP |
281.5±13.0 |
36.2±6.2 |
83.5±13.8 |
106.9±9.3 |
23.2±0.8 |
6.2±1.2 |
200+TP |
277.6±18.7 |
42.9±5.7 |
93.3±19.5 |
119.6±6.2 |
24.9±1.0 |
8.2±1.1* |
600(400)# +TP |
- |
- |
- |
- |
- |
- |
Flutamide +TP |
283.1±7.5 |
6.7±0.9** |
10.8±1.7** |
50.2±4.2** |
11.3±2.6** |
1.3±0.3** |
# Numbers in parenthesis are reduced dose because toxic signs were observed during the study.
- No data because animals died during the study
* Significantly different from vehicle control or vehicle plus TP at P<0.05
** Significantly different from vehicle control or vehicle plus TP at P<0.01
TP Testosterone propionate (TP, CAS No 57-63-6, 98% purity, Sigma) 0.2 mg/kg per day administered subcutaneous injection into the back after oral administration of the chemical
Tamoxifen, an oestrogen antagonist known to act via the estrogen receptor, was shown to inhibit the activity of the alkyl phenols, demonstrating that the assay response was due to interaction with the estrogen receptor.
Endpoint |
Generation |
Sex |
Effect level |
Based on |
Basis for effect level / Remarks |
NOAEL |
other: immature rats |
female |
400 mg/kg bw/day (actual dose received) |
test mat. |
uterine weight (absolute) |
There were no significant differences in the group mean terminal body weights except for the two highest doses (300 and 400 mg/kg) which were reduced to 90% and 77% of the vehicle control group, respectively. The group body weight gain was significantly reduced in the 300 mg/kg dose group (63%) while the 400 mg/kg dose group exhibited no measurable body weight gain.
No treatment related effects on clinical signs were observed for any of the dose groups.
No significant effects were observed in absolute uterine weight. The relative uterine:body weight ratio was increased 1.18 -fold in animals treated with 100, 200, and 300 mg/kg and was elevated 1.31 -fold in animals receiving the top dose (400 mg/kg). The small increases in uterine weight in the absence of any increase in absolute uterine weight are considered to be of no biological significance.
Description of key information
The relative estrogenic potency of Octylphenol (PTOP) was reported in in vitro studies to be 10^3 – 10^5 fold lower compared to estradiol (Routledger & Sumpter, 1997; Laws, 2006).
From the data of two uterotrophic assays it cannot be concluded that octylphenol acts as estrogen agonist or androgen antagonist (Yamasaki, 2003; ICI Surfactant, 1996).
Additional information
Estrogen-like effect:
The relative estrogenic potency of Octylphenol (PTOP) was reported in in vitro studies to be 10^3 – 10^5 fold lower compared to estradiol (Routledger & Sumpter, 1997; Laws, 2006). Receptor binding alone is not sufficient to postulate any estrogenic effect.
Two in vivo uterotrophic assays were conducted. ICI Surfactant (1996) reported a small but significant increases in relative (but not absolute) uterine weight at all dose levels (100-400 mg/kg bw). These changes were within historical control values and considered to be of no biological significance. Yamasaki (2003) conducted a similar test at dose levels of 100, 200 and 600 mg/kg bw. All animals of the high dose group died.Treatment with 200 mg/kg bw resulted in significant body weight loss. The accessory sex organ weight values were within the control ranges in all dose groups. The relative seminal vesicle weights increased significantly but not dose-related in the low-dose group only (50 mg/kg bw 4-tert-ocylphenol). The relative Cowper’s gland weight increased in rats co-administered with TP at 200 mg/kg bw but an apparent dose dependency was not observed. The seminal vesicle weight in this group was within the control ranges of other studies. From the data provided it cannot be concluded that octylphenol acts as an estrogen agonist or androgen antagonist.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
